Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
BASEL, Switzerland and NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV)…